PROSPECTS AND OPPORTUNITIES
Steady growth anticipated despite rising costs and alternative management approaches
Value sales of RX/reimbursement adult incontinence are expected to rise over the forecast period. The ongoing ageing of the population, alongside an increase in obesity-related incontinence cases, will continue to expand the potential user base.
Sustainability and performance enhancements to remain key innovation drivers
Product efficacy in terms of comfort, fit, and absorbency will remain central to innovation efforts. However, sustainability considerations will increasingly dictate the materials used in both product design and packaging.
Distribution to remain focused on prescription-based access with a digital expansion component
RX/reimbursement adult incontinence products will continue to be distributed under the “blue receipt” system, ensuring controlled access through medical prescriptions. However, digital integration is expected to play a more prominent role in improving convenience for users.
Delivery:
Files are delivered directly into your account soon after payment is received and any tax is certification is verified (where applicable).
This report comes in PDF with additional info in Excel included.
Overview:
Understand the latest market trends and future growth opportunities for the Rx/Reimbursement adult incontinence industry in Norway with research from Euromonitor International's team of in-country analysts – experts by industry and geographic specialisation.
Key trends are clearly and succinctly summarised alongside the most current research data available. Understand and assess competitive threats and plan corporate strategy with our qualitative analysis, insight and confident growth projections.
If you're in the Rx/Reimbursement adult incontinence industry in Norway, our research will help you to make informed, intelligent decisions; to recognise and profit from opportunity, or to offer resilience amidst market uncertainty.
The Rx/Reimbursement adult incontinence in Norway report includes:
- Analysis of key supply-side and demand trends
- Detailed segmentation of international and local products
- Historic volume and value sizes, company and brand market shares
- Five year forecasts of market trends and market growth
- Robust and transparent research methodology, conducted in-country
This report answers:
- What is the market size of Rx/Reimbursement adult incontinence in Norway?
- Which are the leading brands in Rx/Reimbursement adult incontinence in Norway?
- How are products distributed in Rx/Reimbursement adult incontinence in Norway?
- How is the rise of e-commerce changing the retail and competitive landscape?
- How has COVID-19 impacted demand? Where have sales increased due to stockpiling amidst national lockdown?
- How have enforced home seclusion and social distancing measures following COVID-19 changed usage patterns for Rx/Reimbursement adult incontinence products?
- Where is future growth expected to be most dynamic?
- How important will sustainability and recycling be in generating future growth?
Rx/Reimbursement Adult Incontinence in Norway - Category analysis
KEY DATA FINDINGS
Ageing population and increased health awareness drive demand
Competitive landscape shaped by Essity’s dominance and product innovation
Distribution remains structured under the ‘blue receipt’ system
Steady growth anticipated despite rising costs and alternative management approaches
Sustainability and performance enhancements to remain key innovation drivers
Distribution to remain focused on prescription-based access with a digital expansion component
Tissue and Hygiene in Norway - Industry Overview
Tissue and hygiene in 2024: The big picture
2024 key trends
Competitive landscape
Retail developments
What next for tissue and hygiene?
DISCLAIMER
Rx/Reimbursement adult incontinence
To qualify for reimbursement, typically a note from a physician is required (a “prescription”) indicating that the patient is in need of incontinence supplies. Depending on the local system in place, supplies are then either shipped directly to consumer home by a designated service or a consumer has to pick up products at a pharmacy. Please be advised that services and routes to consumers can vary even within the same country and vary by state/region. Some countries provide reimbursement through income tax deductions. If this is the case in your market, we EXCLUDE this type of reimbursement from our Rx/Reimbursement coverage as it would be impossible to track. Additionally, consumers would have already purchased the products in retail before claiming tax deductions, and as such the products have already been counted as retail sales. The same logic applies to institutional sales. If a nursing home purchased adult incontinence products from a distributor/manufacturer for distribution to its patients/residents, these products would be included as AFH adult incontinence in our coverage, even though sometimes patients might claim healthcare deductions for costs of stay at a nursing home.
See all of our definitionsWhy buy this report?
- Gain competitive intelligence about market leaders
- Track key industry trends, opportunities and threats
- Inform your marketing, brand, strategy and market development, sales and supply functions
This report originates from Passport, our Rx/Reimbursement adult incontinence research and analysis database.
NEW REPORT GUARANTEE
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extraction Free!